Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial - Concepedia

Concepedia

Publication | Closed Access

Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial

28

Citations

0

References

2004

Year

Yehuda Z. Patt, J. Liebmann, D. Diamandidis, Sabine Eckhardt, Milind Javle, Glen R. Justice, W. Keiser, F. C. Lee, Wilson H. Miller, E. Lin

Journal of Clinical Oncology

Final Safety FindingsGastrointestinal OncologyMedicinePharmacologyColorectal CancerMetastatic Colorectal CancerFirst-line TreatmentPharmacotherapyCancer TreatmentOncologyRadiation Oncology

Abstract

3602